Patents by Inventor Anna Bryland

Anna Bryland has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Crystal Modifications of Odevixibat
    Publication number: 20250019354
    Abstract: The present invention relates to crystal modifications of 1,1-dioxo-3,3-dibutyl-5-phenyl-7-methylthio-8-(N-{(R)-?-[N-((S)-1-carboxypropyl)carbamoyl]-4-hydroxybenzyl}carbamoylmethoxy)-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepine (odevixibat), more specifically crystal modifications 1 and 2 of odevixibat. The invention also relates to a process for the preparation of crystal modification 1 of odevixibat, to a pharmaceutical composition comprising crystal modification 1, and to the use of this crystal modification in the treatment of various conditions as described herein.
    Type: Application
    Filed: July 19, 2024
    Publication date: January 16, 2025
    Inventors: Robert Lundqvist, Ingvar Ymen, Martin Bohlin, Eva Byröd, Per-Göran Gillberg, Anna-Maria Tivert, Jessica Elversson, Nils Ove Gustafsson, Ann-Charlotte Dahlquist, Rikard Bryland
  • Dialysis formulation
    Patent number: 10039783
    Abstract: A replacement fluid for dialysis treatment includes selenium in a concentration of 0.6-1.8 ?M, and rubidium in a concentration of 1.4-4.2 ?M. The replacement fluid is essentially free of one or more of the trace elements selected from chromium, manganese, and copper.
    Type: Grant
    Filed: March 29, 2017
    Date of Patent: August 7, 2018
    Assignee: GAMBRO LUNDIA AB
    Inventors: Anna Bryland, Ola Carlsson, Karin Sandin
  • Dialysis formulation
    Patent number: 10004762
    Abstract: The invention relates to a dialysis formulation, optionally a citrate containing dialysis formulation, comprising selenium (Se), optionally in combination with further trace elements selected from rubidium (Rb), cobalt (Co), molybdenum (Mo), and zinc (Zn). The dialysis formulation is intended to be used in dialysis treatment.
    Type: Grant
    Filed: May 8, 2014
    Date of Patent: June 26, 2018
    Assignee: GAMBRO LUNDIA AB
    Inventors: Anna Bryland, Ola Carlsson, Karin Sandin
  • DIALYSIS FORMULATION
    Publication number: 20170196907
    Abstract: A replacement fluid for dialysis treatment includes selenium in a concentration of 0.6-1.8 ?M, and rubidium in a concentration of 1.4-4.2 ?M. The replacement fluid is essentially free of one or more of the trace elements selected from chromium, manganese, and copper.
    Type: Application
    Filed: March 29, 2017
    Publication date: July 13, 2017
    Inventors: Anna Bryland, Ola Carlsson, Karin Sandin
  • DIALYSIS FORMULATION
    Publication number: 20160067278
    Abstract: The invention relates to a dialysis formulation, optionally a citrate containing dialysis formulation, comprising selenium (Se), optionally in combination with further trace elements selected from rubidium (Rb), cobalt (Co), molybdenum (Mo), and zinc (Zn). The dialysis formulation is intended to be used in dialysis treatment.
    Type: Application
    Filed: May 8, 2014
    Publication date: March 10, 2016
    Applicant: Gambro Lundia AB
    Inventors: Anna Bryland, Ola Carlsson, Karin Sandin